Cargando…

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial

IMPORTANCE: Trivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) are US-licensed for adults aged 65 years and older. Data are needed on the comparative safety, reactogenicity, and health-related quality of life (HRQOL) effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmader, Kenneth E., Liu, Christine K., Harrington, Theresa, Rountree, Wes, Auerbach, Heidi, Walter, Emmanuel B., Barnett, Elizabeth D., Schlaudecker, Elizabeth P., Todd, Chris A., Poniewierski, Marek, Staat, Mary A., Wodi, Patricia, Broder, Karen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809592/ https://www.ncbi.nlm.nih.gov/pubmed/33443580 http://dx.doi.org/10.1001/jamanetworkopen.2020.31266

Ejemplares similares

Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
por: Schmader, Kenneth E., et al.
Publicado: (2023)

A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged
por: Kannan, Senthil, et al.
Publicado: (2015)

A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women
por: Regan, Annette K, et al.
Publicado: (2015)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles
por: Savard, Christian, et al.
Publicado: (2011)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
por: Frolov, Vladimir G., et al.
Publicado: (2008)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant
por: McAdams, David, et al.
Publicado: (2021)

Impact of Trivalent Arsenicals on Selenoprotein Synthesis
por: Ganyc, Denis, et al.
Publicado: (2007)

The Usefulness of Trivalent Phosphorus for the Synthesis of Dendrimers
por: Caminade, Anne-Marie, et al.
Publicado: (2021)

996. A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in US Nursing Homes
por: Gravenstein, Stefan, et al.
Publicado: (2018)

BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine
por: Kannan, Senthil, et al.
Publicado: (2015)

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
por: Rioux, Gervais, et al.
Publicado: (2014)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Trivalent Gd-DOTA reagents for modification of proteins
por: Fisher, Martin J., et al.
Publicado: (2015)

How Plants Handle Trivalent (+3) Elements
por: Poschenrieder, Charlotte, et al.
Publicado: (2019)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia
por: McManus, Meghann, et al.
Publicado: (2013)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Combined Adjuvant Formulations Enhanced an Immune Response of Trivalent Foot and Mouth Disease Vaccine in Cattle
por: Ayele, Getu, et al.
Publicado: (2023)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

THE REVERSAL OF THE SIGN OF THE CHARGE OF COLLODION MEMBRANES BY TRIVALENT CATIONS
por: Loeb, Jacques
Publicado: (1920)

Solid State Reactions Involving Oxides of Trivalent Cations
por: Schneider, S. J., et al.
Publicado: (1961)

Tuning aminopolycarboxylate chelators for efficient complexation of trivalent actinides
por: Pilgrim, Corey D., et al.
Publicado: (2023)

Nonredox trivalent nickel catalyzing nucleophilic electrooxidation of organics
por: Yan, Yuandong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m5v4bo0dm7tjpcpoiv8pvb998h